Piramal Pharma Gets USFDA EIR; US Facility Inspection Closed
Piramal Pharma receives a USFDA Establishment Inspection Report for its US facility, with the inspection classified as Voluntary Action Indicated and officially closed.
Akanksha jain 
Published on: April 2026
It has received the Establishment Inspection Report (EIR) from the US Environmental Protection Agency (EPA) for its US manufacturing facility, with the inspection classified as Voluntary Action Indicated (VAI).
The Piramal Pharma USFDA EIR confirms the closure of the inspection process, indicating that while certain observations were noted, they do not require regulatory enforcement action.
USFDA Inspection Outcome and VAI Classification
The USFDA inspection resulted in a VAI classification, which signifies that observations identified during the audit require corrective action but are not severe enough to trigger warning letters or import alerts.
The issuance of the EIR indicates that the regulator has reviewed and accepted the company’s corrective and preventive actions (CAPA), formally closing the inspection cycle.
Implications for Manufacturing and Compliance
The inspection outcome demonstrates that it continues to meet essential regulatory standards while addressing areas for improvement.
Compliance with USFDA regulations is critical for companies operating in the US market, ensuring uninterrupted supply chains and maintaining product approvals.
- Adherence to quality control standards
- Strong documentation and data integrity
- Efficient manufacturing processes
Role of USFDA in Global Pharmaceutical Oversight
The company conducts routine inspections to ensure compliance with current Good Manufacturing Practices (cGMP).
Inspection outcomes are classified as:
- NAI (No Action Indicated) – Full compliance
- VAI (Voluntary Action Indicated) – Minor observations
- OAI (Official Action Indicated) – Significant violations
Maintaining a favorable inspection record is essential for pharmaceutical companies to sustain global operations and regulatory approvals.
Company Response and Regulatory Position
They stated that the EIR reflects its commitment to quality and regulatory compliance across its operations.
The company continues to strengthen manufacturing systems through:
- Corrective and preventive actions (CAPA)
- Enhanced quality management systems
- Operational improvements
Industry Significance
Regulatory outcomes such as the USFDA EIR VAI classification play a crucial role in shaping the pharmaceutical industry’s operational landscape.
For Indian pharmaceutical companies with global presence, maintaining compliance with international standards is key to sustaining growth and competitiveness.
The development highlights ongoing efforts within the sector to align with stringent regulatory expectations while ensuring uninterrupted supply to key markets.
